| NOVARTIS AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135024 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 05-31-2012 |
| 20120129915 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 05-24-2012 |
| 20120129914 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 05-24-2012 |
| 20120129913 | dsRNA For Treating Viral Infection - The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells. | 05-24-2012 |
| 20120129871 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction - A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, | 05-24-2012 |
| 20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS - The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 05-24-2012 |
| 20120125351 | DISINTEGRABLE ORAL FILMS - A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent. Also provided are methods for preparing the disintegrable oral film and for using the disintegrable film to administer an effective dosage of an active agent into the oral cavity for absorption through the oral mucosa. According to certain embodiments, the disintegrable film includes at least one water soluble polymer and a nicotine active. | 05-24-2012 |
| 20120122977 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors - The present invention provides a compound of formula I; | 05-17-2012 |
| 20120122961 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 05-17-2012 |
| 20120122960 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 05-17-2012 |
| 20120122866 | TOPICAL PHARMACEUTICAL COMPOSITION INCLUDING REL-N-[6-[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]-3-PYRIDINYL]-2-METHYL-4'-(T- RIFLUOROMETHOXY)-[1,1'-BIPHENYL]-3-CARBOXAMIDE - The present invention relates to pharmaceutical compositions of 2-Methyl-4′-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, to the use of such compositions in therapeutic applications and to methods for manufacturing such compositions. | 05-17-2012 |
| 20120122857 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES - The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. | 05-17-2012 |
| 20120122844 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY - The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: | 05-17-2012 |
| 20120122764 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP - The present invention provides a compound of formula I; | 05-17-2012 |
| 20120121714 | COMPOSITIONS WITH ANTIGENS ADSORBED TO CALCIUM PHOSPHATE - Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a pH in the range of 5.5 to 7.5. | 05-17-2012 |
| 20120121585 | SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES - The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation. | 05-17-2012 |
| 20120115934 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 05-10-2012 |
| 20120114744 | COMPOSITIONS AND METHODS TO TREAT MUSCULAR & CARDIOVASCULAR DISORDERS - The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2. | 05-10-2012 |
| 20120114692 | IMMUNOGENIC COMPOSITIONS CONTAINING PHOSPHOLIPID - Immunogenic compositions containing phospholipid adjuvants, including microparticle and emulsion compositions. According to one aspect of the invention, an immunogenic microparticle composition is provided comprising: water; a polymer microparticle; an antigen adsorbed to the microparticle; and a phospholipid compound, e.g., a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a phosphato group and a phosphodiester group; (ii) a plurality of linear alkane groups. According to another aspect of the invention an immunogenic emulsion composition is provided that comprises: water; a metabolizable oil; an emulsifying agent; an antigen; and a phospholipid compound, e.g., a synthetic phospholipid compound like that above. The emulsion composition is an oil-in-water emulsion having oil and aqueous phases, in which the oil phase is in the form of oil droplets, substantially all of which are less than 1 micron in diameter. | 05-10-2012 |
| 20120108657 | DISEASE-ASSOCIATED PROTEIN - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions. | 05-03-2012 |
| 20120108523 | DISEASE-ASSOCIATED PROTEIN - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions. | 05-03-2012 |
| 20120107340 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 05-03-2012 |
| 20120107322 | IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - Compositions for preventing and/or treating | 05-03-2012 |
| 20120107306 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) - The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof. | 05-03-2012 |
| 20120101064 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES - The invention provides compounds of the formula (I): | 04-26-2012 |
| 20120094958 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE - The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof. | 04-19-2012 |
| 20120093860 | INFLUENZA VACCINES WITH INCREASED AMOUNTS OF H3 ANTIGEN - An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight ratio of H3N2:B hemagglutinin is greater than 1. In such a vaccine the weight ratio of H1N1:B hemagglutinin will normally be 1. For example, a vaccine may contain hemagglutinin at 15 μg for A/H1N1, 30 μg for A/H3N2 and 15 μg for B. | 04-19-2012 |
| 20120093859 | INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS - In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a pandemic-associated antigen are administered to a human 1 week apart, 2 weeks apart or 6 weeks apart. Thus the invention provides a method for immunizing a human, comprising steps of: (a) administering to the human a first vaccine comprising antigen from a pandemic-associated influenza virus strain; and then 1/2/6 week(s) later, (b) administering to the same human a second influenza vaccine comprising antigen from the pandemic-associated influenza virus strain. | 04-19-2012 |
| 20120093850 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective | 04-19-2012 |
| 20120083496 | ISOXAZOLE COMPOUND FOR THE TREATMENT OF CANCER - The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis. | 04-05-2012 |
| 20120082681 | ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 04-05-2012 |
| 20120077803 | Uses Of NK Receptor Antagonists - The invention provides the use of a compound of formula (I) | 03-29-2012 |
| 20120077787 | ORGANIC COMPOUNDS - New compounds of the Formula (I): | 03-29-2012 |
| 20120076822 | INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE - Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains. | 03-29-2012 |
| 20120076814 | COMBINATIONS OF PNEUMOCOCCAL RRGB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain. | 03-29-2012 |
| 20120076783 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 03-29-2012 |
| 20120071630 | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and Their Use as Vaccines - The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described. | 03-22-2012 |
| 20120071514 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 03-22-2012 |
| 20120071512 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 - The present invention provides a compound of formula I; | 03-22-2012 |
| 20120071479 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS - Compounds of Formula I: | 03-22-2012 |
| 20120070458 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 03-22-2012 |
| 20120070457 | Polypeptides from neisseria meningitidis - Polypeptides comprising | 03-22-2012 |
| 20120065183 | Tetrahydro-Pyrido-Pyrimidine Derivatives - The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), | 03-15-2012 |
| 20120064532 | Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents - The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A. | 03-15-2012 |
| 20120064104 | COMBINATIONS INCLUDING PNEUMOCOCCAL SEROTYPE 14 SACCHARIDE - Meningococcal lipooligosaccharide and pneumococcal serotype 14 capsular saccharide share an antigen that can cross-react with human tissue. The invention provides various ways of minimising the production of autoreactive antibodies when these two antigens are co-administered. | 03-15-2012 |
| 20120064103 | COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEIN AND PNEUMOCOCCAL SACCHARIDE CONJUGATES - An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis. | 03-15-2012 |
| 20120064086 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 03-15-2012 |
| 20120059049 | BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA - The present invention provides methods and kits for diagnosing and treating glaucoma. | 03-08-2012 |
| 20120059005 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) AN ANTIDIABETIC COMPOUND FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) an insulin sensitivity enhancer compound for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 03-08-2012 |
| 20120045450 | METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 02-23-2012 |
| 20120041052 | Compositions and Methods to Treat Muscular & Cardiovascular Disorders - The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2. | 02-16-2012 |
| 20120039934 | ADJUVANT-SPARING MULTI-DOSE INFLUENZA VACCINATION REGIMEN - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 02-16-2012 |
| 20120038073 | SPRAY DRYING METHODS AND RELATED COMPOSITIONS - A method and apparatus are provided for atomizing a liquid under dispersal conditions suitable for spray drying at a commercial plant scale. In one embodiment, a liquid atomizer has a structural body adapted for connection with a spray dryer and a plurality of atomizing nozzles. Each of the atomizing nozzles includes a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas. In another embodiment, a process for producing a powder blend of at least two target substances in a single processing step is provided. | 02-16-2012 |
| 20120035174 | Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide - Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized. | 02-09-2012 |
| 20120035168 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES - The invention relates to compound of the formula I | 02-09-2012 |
| 20120034650 | Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof - The present invention relates to the provision of a polynucleotide comprising one or more functional fragments of a biosynthetic gene cluster involved in the production of a compound of formula (I) or (I′). The present invention also provides a method of preparing a compound of formula (I) or (I′) or of formula (II) to (VII), (XI) to (XIV) and (XVII) and (XVIII). Moreover, the use of such compound as a pharmaceutical composition is also provided in the present invention. | 02-09-2012 |
| 20120034262 | Bovine Herpes Virus-1 Compositions, Vaccines and Methods - The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens. | 02-09-2012 |
| 20120034231 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 02-09-2012 |
| 20120029084 | Topical Nepafenac Formulations - Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration. | 02-02-2012 |
| 20120029053 | Short Interfering Ribonucleic Acid (siRNA) for Oral Administration - Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification. | 02-02-2012 |
| 20120029052 | Short Interfering Ribonucleic Acid (siRNA) for Oral Administration - Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification. | 02-02-2012 |
| 20120028969 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF - The present invention provides compounds of formula (I); | 02-02-2012 |
| 20120027801 | POLYPEPTIDES FROM NEISSERIA MENINGITIDIS - Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis. | 02-02-2012 |
| 20120022139 | Short Interfering Ribonucleic Acid (siRNA) for Oral Administration - Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification. | 01-26-2012 |
| 20120015973 | MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS - The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided. | 01-19-2012 |
| 20120015968 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER-AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) - The invention relates to the use of a pyrimidylaminobenzamide derivative of formula I | 01-19-2012 |
| 20120015907 | Furopyridine compounds and uses thereof - The present invention provides a compound of formula I; | 01-19-2012 |
| 20120014906 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-19-2012 |
| 20120010418 | Process for Making N-Hydroxy-3[4-[[[2-(2methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2- -propenamide and Starting Materials Therefor - N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and starting materials therefore are prepared by new synthetic methods. | 01-12-2012 |
| 20120010398 | PURIFICATION METHOD - A process for purifying a | 01-12-2012 |
| 20120010135 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE - The present invention provides spiro derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-12-2012 |
| 20120004164 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-05-2012 |
| 20120003367 | DIETARY FIBER COMPOSITION - The present invention provides a chewable composition containing granules of water-soluble dietary fiber. The chewable composition has highly agreeable organolpetic properties and is consumable without the need of an ingestion aid. | 01-05-2012 |
| 20120003258 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 01-05-2012 |
| 20120003219 | Compositions and Methods to Treat Bone Related Disorders - The present invention relates to the use of modulators of the sclerostin:sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin:sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 01-05-2012 |
| 20120003211 | IMMUNOGLOBULINS WITH REDUCED AGGREGATION - The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease. | 01-05-2012 |
| 20110319992 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a hydrophilic side-chain macromer for glistening resistance. | 12-29-2011 |
| 20110319614 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 12-29-2011 |
| 20110319457 | DEFERACIROX DISPERSIBLE TABLETS - The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. | 12-29-2011 |
| 20110319329 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache. | 12-29-2011 |
| 20110318366 | BIOLOGIC COMPOUNDS - The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders. | 12-29-2011 |
| 20110313518 | HIGH REFRACTIVE INDEX, ACRYLIC OPHTHALMIC DEVICE MATERIALS WITH REDUCED GLISTENINGS - High refractive index copolymers with reduced glistenings are disclosed. The copolymers, which are particularly suitable for use as ophthalmic device materials, comprise a high molecular weight, reactive, linear polyethylene glycol component. | 12-22-2011 |
| 20110312510 | High-Throughput Complement-Mediated Antibody-Dependent and Opsonic Bactericidal Assays - The disclosure provides methods and kits for performing automated high-throughput assays to measure bactericidal activity in samples, such as plasma or sera from vaccinated subjects to evaluate the efficacy of vaccines against bacterial pathogens. The method combines obligatory linear-range data analysis, plate sealing and liquid volume handling for all assay steps to provide an automated, high-throughput measurement of bactericidal activity with favorable inter-assay and inter-operator variability. | 12-22-2011 |
| 20110311576 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH NON-HIB VACCINES - An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from | 12-22-2011 |
| 20110311575 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES - A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine. | 12-22-2011 |
| 20110308515 | ELECTRONICALLY CONTROLLABLE AEROSOL DELIVERY - An aerosolization device comprises a housing having an inlet and an outlet and an airway extending from the inlet to the outlet. A valve in the airway comprises a piezoelectric element which controls the valve, and a reservoir in communication with the airway is adapted to contain a pharmaceutical formulation so that the pharmaceutical formulation may be introduced into the airway and passed through the outlet in an aerosolized form. The piezoelectric element may alternatively or additionally be used to sense a condition in the aerosolization device. | 12-22-2011 |
| 20110306672 | CERAMIDE-ANALOGOUS METABOLITES - This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis. | 12-15-2011 |
| 20110306659 | OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION - Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine. | 12-15-2011 |
| 20110306625 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. | 12-15-2011 |
| 20110306095 | METHODS FOR SELECTING EUKARYOTIC CELLS EXPRESSING A HETEROLOGOUS PROTEIN - The invention pertains to a method for selecting at least one eukaryotic host cell expressing a product of interest, comprising
| 12-15-2011 |
| 20110306092 | EXPRESSION VECTOR SYSTEM COMPRISING TWO SELECTION MARKERS - The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least
| 12-15-2011 |
| 20110305727 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 12-15-2011 |
| 20110301184 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR - A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use. | 12-08-2011 |
| 20110301100 | Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent. | 12-08-2011 |
| 20110300205 | SELF REPLICATING RNA MOLECULES AND USES THEREOF - This application discloses self-replicating RNA molecules that contain modified nucleotides, compositions that contain the self-replicating RNA molecules, and methods for using the self-replicating RNA molecules, for example, to raise an immune response. | 12-08-2011 |
| 20110297755 | PREFILMING ATOMIZER - A method of forming droplets comprises flowing a liquid through a channel; spreading the liquid into a thin film in the channel; and impinging the thin film with a flowing gas to atomize the liquid into droplets. The droplets may then be dried to produce dried particles, such as particles comprising a pharmaceutical active agent. The droplets formed by the disclosed process have improved size and/or size distribution characteristics. | 12-08-2011 |
| 20110294861 | METHOD OF TREATMENT OF HEREDITARY HEMOCHROMATOSIS - The present invention relates to the use of Compound I of the following formula | 12-01-2011 |
| 20110288144 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA - The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof. | 11-24-2011 |
| 20110288057 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS - The invention relates to the use of and mainly novel compounds of the formula I | 11-24-2011 |
| 20110287415 | IN-SITU HYBRIDIZATION TO DETECT RNA AND DNA MARKERS - The present invention provides probes, kits and methods for specifically binding mRNA of target cells, e.g., fetal cells, that allows visualization of the target cells, under conditions that allows a second probe to specifically bind the target cell's chromosomal DNA. | 11-24-2011 |
| 20110282053 | Organic Compounds - A process for preparing compounds of formula I | 11-17-2011 |
| 20110281845 | ORGANIC COMPOUNDS - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 11-17-2011 |
| 20110281751 | CELL SURFACE DISPLAY OF POLYPEPTIDE ISOFORMS BY STOP CODON READTHROUGH - The present invention inter alia pertains to a method for generating or selecting a eukaryotic host cell expressing a desired level of a polypeptide of interest, comprising:
| 11-17-2011 |
| 20110277752 | RECEPTACLE FOR AN AEROSOLIZABLE PHARMACEUTICAL FORMULATION - An article for storing a pharmaceutical formulation. In one or more embodiments, the present invention comprises a receptacle ( | 11-17-2011 |
| 20110275819 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 11-10-2011 |
| 20110275613 | ORGANIC COMPOUNDS - The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by | 11-10-2011 |
| 20110275535 | Yeast Display Systems - The present invention relates to the field of protein display libraries and library screening. In preferred embodiments, the present invention provides a three component system for display comprising a cell surface molecule, an adapter molecule and a display molecule. | 11-10-2011 |
| 20110275132 | PURIFICATION OF BACTERIAL ANTIGENS - Presented are methods of isolation of pili and pilus-like structures from Gram-positive bacteria including | 11-10-2011 |
| 20110275102 | ACTIVATION OF MUTATED RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 11-10-2011 |
| 20110263681 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 10-27-2011 |
| 20110263560 | Organic Compounds - 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification. | 10-27-2011 |
| 20110262520 | LAYERED DRUG DELIVERY DEVICE - The layered drug delivery devices of the present invention have an outer side and an inner side. The device includes, in order from the outer side to the inner side, a first layer and a second layer. The first layer wherein the first layer is water insoluble, water swellable, and water permeable. The second layer includes a therapeutic amount of a water soluble drug and a water soluble mucoadhesive film. The second layer is disposed such that water passing through said first layer solubilizes the drug. The said solubilized drug then can permeate through a mucosal membrane when the inner side is in contact with the mucosal membrane. The drug delivery device is in sheet form. | 10-27-2011 |
| 20110257291 | Ophthalmic and Otorhinolaryngological Device Materials - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a hydrophilic side-chain macromer for glistening resistance. | 10-20-2011 |
| 20110257131 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS - (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, | 10-20-2011 |
| 20110257104 | METHODS TO IDENTIFY MACROMOLECULE BINDING AND AGGREGATION PRONE REGIONS IN PROTEINS AND USES THEREFOR - The present invention provides methods and computational tools based, at least in part, on computer simulations that identify macromolecule binding regions and aggregation prone regions of a protein. Substitutions may then be made in these aggregation prone regions to engineer proteins with enhanced stability and/or a reduced propensity for aggregation. Similarly, substitutions may then be made in these macromolecule binding regions to engineer proteins with altered binding affinity for the macromolecule. | 10-20-2011 |
| 20110251202 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors - The invention relates to novel organic compounds of formula (I) | 10-13-2011 |
| 20110251125 | DISODIUM SALTS, MONOHYDRATES, AND ETHANOL SOLVATES FOR DELIVERING ACTIVE AGENTS - The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. The delivery agents have the formula | 10-13-2011 |
| 20110245274 | ISOXAZOLINES DERIVATIVES AND THEIR USE AS PESTICIDE - Novel isoxazoline compounds, compositions containing the compounds and methods for making the compounds are disclosed. The compounds and compositions have pesticidal properties and are suitable for controlling ectoparasites on non-human animals. | 10-06-2011 |
| 20110245256 | USE OF A PKC INHIBITOR - The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling. | 10-06-2011 |
| 20110237674 | TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT - Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain. | 09-29-2011 |
| 20110237616 | PHEHYLEPHRINE FORMULATIONS WITH IMPROVEDS STABILITY - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 09-29-2011 |
| 20110237572 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives - A compound of Formula I | 09-29-2011 |
| 20110237498 | SOLUBLE POLYPEPTIDES FOR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRPα (CD172a) or functional derivatives which bind to human CD47. | 09-29-2011 |
| 20110236489 | VACCINE ADJUVANT COMBINATIONS - An immunological adjuvant comprises an oil-in-water emulsion, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be combined with immunogens for preparing vaccines. | 09-29-2011 |
| 20110230499 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT - The use of a Hsp90 inhibitor for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis. | 09-22-2011 |
| 20110230457 | Substituted Isoquinolinones and Quinazolinones - The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) | 09-22-2011 |
| 20110230444 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR - A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders. | 09-22-2011 |
| 20110230403 | GLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention relates to compounds of formula I | 09-22-2011 |
| 20110229501 | ORGANIC COMPOUNDS - The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C | 09-22-2011 |
| 20110224173 | C2-C5-Alkyl-Imidazole-Bisphosphonates | 09-15-2011 |
| 20110218145 | ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES - High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples. | 09-08-2011 |
| 20110212950 | 4,4-DISUBSTITUTED PIPERIDINES - The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R | 09-01-2011 |
| 20110206690 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. | 08-25-2011 |
| 20110201606 | PYRIMIDINE DERIVATIVES - Novel pyrimidine derivatives of formula I | 08-18-2011 |
| 20110200582 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM - Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). | 08-18-2011 |
| 20110195966 | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) a mTOR inhibitor for the treatment of a target of rapamycin (mTOR) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 08-11-2011 |
| 20110195077 | METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage. | 08-11-2011 |
| 20110190398 | USE OF IMMUNOSUPPRESSANT COMPOUNDS IN A NEW INDICATION - A compound of formula V or formula VI for use in the treatment of a demyelinating peripheral neuropathy: wherein X is O, S, SO or SO | 08-04-2011 |
| 20110190334 | Heterocyclic Sulfonamide Derivatives - The present invention relates to compounds of Formula I | 08-04-2011 |
| 20110190258 | ARYL BENZYLAMINE COMPOUNDS - The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them. | 08-04-2011 |
| 20110184328 | JOINT PAIN TREATMENT BANDAGE - The invention relates to a medical bandage, which comprises at least two transdermal patches, and wherein said at least two transdermal patches each comprise a pain-relieving pharmaceutically active substance such as an NSAID. | 07-28-2011 |
| 20110183964 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B - The present teachings relate to compounds of Formula I: | 07-28-2011 |
| 20110183962 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS - The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors. | 07-28-2011 |
| 20110183955 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases. | 07-28-2011 |
| 20110178097 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-Q- UINOLIN-2-ONE LACTIC ACID SALTS - The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts. | 07-21-2011 |
| 20110178085 | Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide - Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized. | 07-21-2011 |
| 20110172178 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES - It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. | 07-14-2011 |
| 20110172157 | SOMATOSTATIN ANALOGUES - The invention provides cyclo[{4-(NH | 07-14-2011 |
| 20110171159 | Glycoside Derivatives and Uses Thereof - This invention relates to compounds represented by formula (I): | 07-14-2011 |
| 20110166320 | SOMATOSTATIN ANALOGUES - The invention provides cyclo[{4-(NH | 07-07-2011 |
| 20110166058 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 07-07-2011 |
| 20110165097 | COMPOSITIONS FOR PERCUTANEOUS ADMINISTRATION - Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Sasd compositions are characterized by having an exeefenf long term efficacy due to their ability to form a long-lasting film on the skin. | 07-07-2011 |
| 20110152244 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. | 06-23-2011 |
| 20110150760 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 06-23-2011 |
| 20110144352 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF - The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers. | 06-16-2011 |
| 20110142849 | PCSK9 ANTAGONISTS - The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies. | 06-16-2011 |
| 20110139784 | POUCH - A pouch for containing a product, the pouch comprising a first wall ( | 06-16-2011 |
| 20110136146 | BIOASSAY FOR POLYQ PROTEIN - The present invention relates to bioassays for mutated polyQ protein associated with disease and their use as diagnostic tools, for monitoring disease progression or for monitoring the efficacy of treatment of the disease. In a preferred embodiment the polyQ-protein is polyQ-huntingtin. | 06-09-2011 |
| 20110135691 | IMMUNOMODULATION BY IAP INHIBITORS - The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided. | 06-09-2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES - The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits. | 06-09-2011 |
| 20110135668 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof. | 06-09-2011 |
| 20110130399 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity - The invention relates to new phthalazine derivatives of formula I, | 06-02-2011 |
| 20110129517 | TABLETTABLE CHEWING GUMS - The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking. | 06-02-2011 |
| 20110124701 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): | 05-26-2011 |
| 20110123626 | PULMONARY DELIVERY OF A FLUOROQUINOLONE - A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 μm to about 5 μm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as | 05-26-2011 |
| 20110117127 | ANALYSIS OF DNA BY MEANS OF CAPILLARY ELECTROPHORESIS - The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination. | 05-19-2011 |
| 20110112308 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]ph- enyl]-2E-2-propenamide - Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared and characterized. | 05-12-2011 |
| 20110110967 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 05-12-2011 |
| 20110105521 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 05-05-2011 |
| 20110098280 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS - Novel pyrimidine derivatives of formula I | 04-28-2011 |
| 20110097716 | Methods for Detecting Oligonucleotides - The invention provides methods and compositions for detecting and/or quantifying nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic target oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample. | 04-28-2011 |
| 20110092693 | NOVEL COMPOUNDS - The present invention relates to a process for the preparation of an oligomeric compound made up of two or more individual oligomers, in which said oligomeric compound the individual oligomers are separated by a photocleavable linker, comprising the step of photoactively cleaving said linker. | 04-21-2011 |
| 20110092491 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with cSRC, Lck, FGFR3, Flt3, TrkB, Bmx, and/or PFGFRα kinase activity. | 04-21-2011 |
| 20110092426 | ORAL CALCITONIN COMPOSITIONS AND APPLICATIONS THEREOF - The present invention relates to compositions for the oral delivery of pharmacologically active calcitonin, to methods of synergistically enhancing the biological effects of orally administered calcitonin with D type vitamins and calcium, and to methods of treating and/or preventing disease in mammals, particularly humans, by orally administering calcitonin compositions in accordance with the invention. | 04-21-2011 |
| 20110091492 | ESCHERICHIA COLI IMMUNOGENS WITH IMPROVED SOLUBILITY - Variants of the pathogenic | 04-21-2011 |
| 20110082076 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE - Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (T | 04-07-2011 |
| 20110071165 | Aza- and polyazanthranyl amides and their use as medicaments - Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides. | 03-24-2011 |
| 20110070247 | PROTEIN MODULATORS - The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma. | 03-24-2011 |
| 20110065732 | KIT FOR TOPICAL APPLICATION OF MEDICATION - The application describes a convenient portable kit for the application of topical medications. The kit can be used, for example, as a convenient system for application of cold sore medication. The kit includes a container for a quantity of fluid medication sufficient for several treatments together with a plurality of applicators for said medicine. The applicators are specially designed to apply the medicine accurately and with minimal pain. | 03-17-2011 |
| 20110065708 | HETEROCYCLIC OXIME COMPOUNDS - The invention relates to compounds of formula (I) and salts thereof: | 03-17-2011 |
| 20110060004 | Imidazo-Pyridine Derivatives as Activin-Like Receptor Kinase (ALK4 or ALK5) Inhibitors - Compounds of formula (I): in free or salt or solvate form, where X, R | 03-10-2011 |
| 20110057337 | PLASTIC CASTINGS MOLDS - The invention is concerned with the problem that with known plastic casting moulds, especially those of polypropylene, the lenses produced with these moulds have a slippery surface. The invention solves this problem through the use of polymers which are notable for their very low oxygen permeability. | 03-10-2011 |
| 20110053893 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS - The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine. | 03-03-2011 |
| 20110046376 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. - A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reacted in a solvent that comprises water in an amount greater than 50 percent by volume based on the amount of the solvent and/or are reacted in a solvent that comprises an organic solvent component that has a boiling point of greater than 100° C. at atmospheric pressure. | 02-24-2011 |
| 20110046193 | DEFERACIROX DISPERSIBLE TABLETS - The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. | 02-24-2011 |
| 20110045536 | MAMMALIAN EXPRESSION VECTOR - The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising (a) at least one expression cassette (POI) for expressing a polypeptide of interest; (b) an expression cassette (MSM) comprising a mammalian selectable marker gene; (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; wherein the expression cassette (POI) is flanked 5′ by the expression cassette (MASM), the expression cassette (MSM) is located 3′ from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5′ to 3′ orientation. Also provided are host cells, comprising said vector and methods for producing a polypeptide using respective host cells. | 02-24-2011 |
| 20110045457 | ASSAYS FOR ADSORBED INFLUENZA VACCINES - Influenza hemagglutinin (HA) binds to aluminium salt adjuvants and cannot easily be directly assayed directly a single radial immunodiffusion (SRID) test. The invention modifies the SRID protocol for an adsorbed antigen by including a step in which antigen is desorbed prior to diffusion. | 02-24-2011 |
| 20110039759 | Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) - The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to the normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. The invention provide method of treating cystic fibrosis or COPD in a patient by administering to said patient an effective amount of an agent which triggers anion efflux in respiratory tissue via the activation of the secretin receptor. | 02-17-2011 |
| 20110038900 | NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS - In various aspects of the present invention, nanoparticle compositions are provided which comprise (a) nanoparticles comprising at least one biodegradable polymer and (b) at least one pharmaceutical associated with the nanoparticles. In other aspects of the present invention, methods of forming nanoparticles compositions are provided, which comprise contacting a first liquid that comprises one or more biodegradable polymers dissolved in a first solvent with a second liquid that comprises a second solvent which is miscible with the first solvent while being a non-solvent for the one or more biodegradable polymers, such that nanoparticles are formed. | 02-17-2011 |
| 20110038879 | IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - Compositions for preventing and/or treating | 02-17-2011 |
| 20110034531 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA - The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
| 20110032474 | LENS HAVING AN OPTICALLY CONTROLLED PERIPHERAL PORTION AND A METHOD FOR DESIGNING AND MANUFACTURING THE LENS - A contact lens or phakic IOC lens is provided with a peripheral portion that has a power profile that provides optical control of peripheral vision images. Typically, the central portion of the lens is also provided with optical control. The power profile of the lens at the boundary of the central and peripheral portions meets certain boundary conditions that ensure that the lens provides a desired or selected vision correction. Because the peripheral portion of the lens provides optical control that defocuses the peripheral vision image relative to the retina, the lens can be used to prevent or inhibit growth of the eye, thereby preventing or inhibiting myopia or the effects of myopia. | 02-10-2011 |
| 20110027284 | NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF - The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system. | 02-03-2011 |
| 20110022023 | UNITARY WITHDRAWAL SPIKE UNIT SUITABLE FOR FACTORY FITTING - A withdrawal spike unit ( | 01-27-2011 |
| 20110021530 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS - Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R | 01-27-2011 |
| 20110014230 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS - A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer. | 01-20-2011 |
| 20110014225 | CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION - Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive | 01-20-2011 |
| 20110009459 | EPOTHILONE DERIVATIVES - Epothilone derivatives of Formula (I) and their use as a pharmaceutical. | 01-13-2011 |
| 20110009340 | COMBINATION OF AN IRON CHELATOR AND AN IMMUNOSUPPRESSANT AND USE THEREOF - The invention relates to a combination comprising an iron chelator and an immunosuppressant, to the use of such combination for the improvement of immunosuppression, e.g. in hematopoietic stem cell transplantation. | 01-13-2011 |
| 20110003300 | RAPID STERILITY MICROASSAY - The present invention relates to a method for detecting a viable microorganism in a pharmaceutical composition comprising the steps of providing a filterable pharmaceutical composition; filtering the pharmaceutical composition to provide at least three membranes upon which the pharmaceutical composition is deposited, placing the three membranes onto solid culture media to produce at least three filtrand cultures, culturing under aerobic and anaerobic conditions and detecting a viable microorganism cell, micro-colony or colony, wherein the presence of a viable cell, micro-colony or colony on the membrane indicates the presence of a viable microorganism in the pharmaceutical composition. | 01-06-2011 |
